The molecular pathological basis and potential clinical applications of ‘zero‐budding’ status in stage II colorectal cancer
Abstract In the personalized management of stage II colorectal cancer (CRC), traditional TNM (Tumor, Node, Metastasis) staging has limited ability to accurately stratify the risk of postoperative recurrence. Consequently, oncologists frequently face a major therapeutic dilemma when determining the use of adjuvant chemo...